Los Angeles Capital Management LLC bought a new position in Outset Medical, Inc. (NASDAQ:OM)

Los Angeles Capital Management LLC purchased a new position in shares of Outset Medical, Inc. (NASDAQ:OM – Free Report) in the second quarter, HoldingsChannel reports. The fund acquired 189,780 shares of the company’s stock, valued at approximately $731,000.

Other hedge funds have recently modified their positions in the company. Mubadala Investment Co PJSC acquired a new position in Outset Medical in the fourth quarter worth $7,794,000. PFM Health Sciences LP purchased a new position in shares of Outset Medical during the 4th quarter worth about $5,406,000. Acadian Asset Management LLC boosted its holdings in shares of Outset Medical by 369.4% in the first quarter. Acadian Asset Management LLC now owns 779,242 shares of the company’s stock valued at $1,728,000 after purchasing an additional 613,229 shares in the last quarter. Assenagon Asset Management SA boosted its position in shares of Outset Medical by 60.4% in the second quarter. Assenagon Asset Management SA now owns 1,515,126 shares of the company’s stock valued at $5,833,000 after acquiring an additional 570,281 shares in the last quarter. Finally, GSA Capital Partners LLP boosted its holdings in Outset Medical by 508.9% during the fourth quarter. GSA Capital Partners LLP now owns 514,317 shares of the company’s stock worth $2,782,000 after purchasing an additional 429,851 shares during the last quarter.

The Wall Street analyst weighs in

A number of research analysts have weighed in on OM shares. TD Cowen cut their price target on Outset Medical from $9.00 to $3.00 and set a “buy” rating for the company in a research note on Thursday, August 8th. Royal Bank of Canada lowered shares of Outset Medical from an “outperform” rating to a “sector perform” rating and decreased their price target for the company from $6.00 to $3.00 in a research note on Thursday. August 8. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $4.64.

Read our latest report on Outset Medical

Medical price performance in the beginning

NASDAQ:OM opened at $0.53 on Friday. Outset Medical, Inc. has a 12-month low of $0.44 and a 12-month high of $13.20. The firm has a market cap of $27.41 million, a price-to-earnings ratio of -0.16 and a beta of 1.92. The stock’s 50-day moving average price is $2.12, and its two-hundred-day moving average price is $2.78. The company has a quick ratio of 5.38, a current ratio of 6.80, and a debt-to-equity ratio of 2.87.

Outset Medical (NASDAQ:OM – Get Free Report ) last announced its quarterly earnings results on Wednesday, August 7th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.07). Outset Medical had a negative net margin of 136.72% and a negative return on equity of 143.52%. The business had revenue of $27.39 million for the quarter, compared to analyst estimates of $31.19 million. During the same period in the previous year, the company earned ($0.90) EPS. On average, analysts anticipate that Outset Medical, Inc. will post -2.52 earnings per share for the current year.

About Outset Medical

(Free Report)

Outset Medical, Inc, a medical technology company, is engaged in the development of a hemodialysis system for hemodialysis in the United States. The company offers the Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for acute and home dialysis care; and manufactures, supports and distributes the Tablo console, Tablo cartridge and other consumables.

See Also

Want to see what other hedge funds own OM? Visit HoldingsChannel.com to get the latest 13F filings and insider trading for Outset Medical, Inc. (NASDAQ:OM – Free Report).

Get news and reviews for Outset Medical Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Outset Medical and related companies with MarketBeat.com’s FREE daily email newsletter.